Vardenafil (Levitra/Staxyn) and Finasteride Interaction

Why These Two Drugs Are Frequently Co-Prescribed

Men over 40 commonly present with both erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) or male-pattern hair loss. The prevalence of ED rises from roughly 12% in men aged 40-49 to over 40% in men aged 60-69, according to data from the Massachusetts Male Aging Study [1]. Finasteride, meanwhile, is one of only two FDA-approved oral treatments for androgenetic alopecia and remains a first-line BPH therapy per the American Urological Association (AUA) guidelines [2].

A 2019 cross-sectional analysis published in The Journal of Sexual Medicine found that approximately 18.5% of men filling PDE5 inhibitor prescriptions were concurrently taking a 5-alpha reductase inhibitor (5-ARI) [3]. This overlap makes the vardenafil-finasteride pair a frequent question in both urology and primary care clinics. The good news: no direct pharmacokinetic clash exists between these two molecules. The nuance sits in their pharmacodynamic profiles, where finasteride's own sexual side-effect burden may complicate the clinical picture for a man already seeking help for ED.

Pharmacokinetic Profile: How Each Drug Is Metabolized

Vardenafil is primarily metabolized by hepatic CYP3A4, with minor contributions from CYP3A5 and CYP2C isoforms. Its major active metabolite, M1 (desethyl-vardenafil), accounts for about 7% of total PDE5 inhibitory activity [4]. The FDA-approved Levitra label lists strong CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin) as drugs requiring dose adjustment, typically reducing vardenafil to 5 mg or less [4].

Finasteride is also a CYP3A4 substrate, but it does not inhibit or induce CYP3A4, CYP2D6, CYP1A2, CYP2C9, or CYP2C19 at clinically relevant concentrations [5]. The Proscar prescribing information explicitly states that no drug interaction studies demonstrated clinically meaningful effects [5]. Finasteride's half-life is 5-6 hours in men aged 18-60, extending to approximately 8 hours in men over 70.

Because finasteride does not inhibit CYP3A4, it will not raise vardenafil plasma concentrations. No dose adjustment for either drug is required on pharmacokinetic grounds alone. This stands in contrast to combinations like vardenafil plus ketoconazole, where a 10-fold AUC increase forces mandatory dose reduction [4].

Pharmacodynamic Considerations: Where the Real Questions Arise

The interaction between vardenafil and finasteride is pharmacodynamic, not pharmacokinetic. Both drugs affect male sexual physiology through separate but connected pathways.

Vardenafil inhibits PDE5, increasing cyclic GMP in penile smooth muscle, which promotes blood flow and erection. Its onset is 25-60 minutes, with a plasma half-life of 4-5 hours [4]. Finasteride blocks type II 5-alpha reductase, reducing conversion of testosterone to dihydrotestosterone (DHT) by approximately 70% at the 5 mg dose and roughly 65% at the 1 mg dose [5][6].

DHT is the primary androgen driving prostate growth and scalp hair miniaturization. It also plays a role in libido, penile tissue maintenance, and ejaculatory function. The PLESS trial (N=3,040), a 4-year study of finasteride 5 mg for BPH, reported decreased libido in 6.4% of finasteride-treated men versus 3.4% on placebo, and ED in 8.1% versus 3.7% [7]. At the 1 mg hair-loss dose, sexual side effects were reported in 3.8% of men in the key registration trials, versus 2.1% on placebo [6].

The clinical question becomes: if finasteride is contributing to a patient's ED, is adding vardenafil the right approach, or should the 5-ARI be reconsidered? Both options are valid, and the answer depends on the patient's priorities.

Blood Pressure and Cardiovascular Overlap

Vardenafil produces modest systemic vasodilation. In healthy volunteers, single doses of 20 mg lowered supine systolic blood pressure by a mean of 7 mmHg and diastolic by 8 mmHg, with peak effects at 1-4 hours post-dose [4]. This is clinically significant primarily when combined with nitrates (absolutely contraindicated) or alpha-blockers (requires timing separation and dose titration).

Finasteride has no direct cardiovascular or hemodynamic effects. It does not lower blood pressure, alter heart rate, or interact with nitric oxide signaling [5]. This means the vardenafil-finasteride combination carries no additive hypotensive risk beyond what vardenafil produces alone.

For men who also take tamsulosin for BPH (a common three-drug scenario), the hemodynamic picture changes. The FDA Levitra label warns that concomitant alpha-blockers may cause symptomatic hypotension, and recommends that vardenafil 5 mg not be taken within 6 hours of an alpha-blocker dose [4]. This is a separate interaction from the finasteride question but often relevant in the same patient population.

Clinical Evidence: PDE5 Inhibitors in Men on 5-Alpha Reductase Inhibitors

Several trials have examined PDE5 inhibitor use in men receiving 5-ARIs. The CombAT trial (N=4,844) studied dutasteride (a dual 5-ARI) plus tamsulosin for BPH and reported ED rates of 6.3% with combination therapy over 4 years [8]. While this trial used dutasteride rather than finasteride, the mechanism of DHT suppression is analogous.

A randomized controlled trial by Glina et al. (2004) evaluated the addition of a PDE5 inhibitor to finasteride therapy in men with both BPH and ED [9]. Men who added the PDE5 inhibitor showed a mean IIEF-EF domain improvement of 7.4 points from baseline (versus 1.2 points for placebo add-on), demonstrating that PDE5 inhibition remains effective despite ongoing DHT suppression.

The American Urological Association's 2018 guideline on ED states: "PDE5 inhibitors are recommended as first-line therapy for the management of erectile dysfunction" and notes that they can be used concurrently with other medications for BPH, including 5-ARIs, provided no pharmacokinetic contraindication exists [10]. The Endocrine Society's 2018 guideline on testosterone therapy also acknowledges that DHT-suppressing agents may affect sexual function and that PDE5 inhibitors remain appropriate adjunctive therapy [11].

Monitoring Recommendations for the Combination

Baseline assessment before starting both drugs together should include the International Index of Erectile Function (IIEF-5) score, a blood pressure reading, serum PSA (finasteride halves PSA values, requiring the "multiply by 2" correction for screening), and a basic metabolic panel if renal concerns exist [5][12].

Follow-up at 3 months should reassess:

• IIEF-5 score to determine if vardenafil is providing adequate response
• Sexual side-effect inventory (libido, ejaculatory function, orgasm)
• Blood pressure, particularly if the patient also takes antihypertensives
• PSA (remembering the 2x correction factor while on finasteride)

If a patient reports worsening ED despite vardenafil, clinicians should consider whether finasteride itself is the contributing factor. A trial discontinuation of the 5-ARI for 3-6 months, with continued PDE5 inhibitor use, can help differentiate the cause [10]. For BPH patients, switching from finasteride to tamsulosin monotherapy is one option, though this sacrifices the prostate volume reduction that 5-ARIs provide.

Dose Adjustments and Practical Prescribing

No dose adjustment of either drug is required when they are combined. Vardenafil dosing follows standard guidelines:

• Starting dose: 10 mg taken approximately 60 minutes before sexual activity
• Dose range: 5 mg to 20 mg based on efficacy and tolerability
• Maximum frequency: once per 24 hours
• For Staxyn (orally disintegrating tablet): 10 mg, not interchangeable with Levitra film-coated tablets due to higher bioavailability [4]

Finasteride dosing is indication-dependent:

• Androgenetic alopecia: 1 mg daily (Propecia)
• BPH: 5 mg daily (Proscar)

There is no timing restriction between the two medications. Finasteride is taken daily regardless of sexual activity, while vardenafil is used on-demand. Patients should be counseled that vardenafil requires sexual stimulation to work and should not be taken with a high-fat meal, which can reduce C-max by 18-50% [4].

The Post-Finasteride Syndrome Debate and Its Relevance

A small subset of men report persistent sexual, neurological, and cognitive symptoms after discontinuing finasteride, a phenomenon termed post-finasteride syndrome (PFS). The NIH-funded PFS Foundation registry has collected over 10,000 self-reported cases, and a 2012 study by Irwig and Kolukula found that 94% of men who developed sexual side effects on finasteride 1 mg reported persistent symptoms for a median of 40 months after stopping the drug [13].

This remains controversial. A 2021 meta-analysis in JAMA Dermatology (N=17,985 across 34 RCTs) concluded that finasteride at the 1 mg dose was associated with a statistically significant but small increase in sexual dysfunction (RR 1.55, 95% CI 1.20-2.01), with most cases resolving after discontinuation [14]. The AUA has not formally recognized PFS as a distinct syndrome but does recommend informed consent regarding sexual side effects before prescribing finasteride.

For men who are concerned about PFS, prescribing vardenafil "just in case" is not appropriate. A frank discussion about the probability (roughly 2-4% excess risk over placebo at the 1 mg dose) and the option to discontinue finasteride if sexual symptoms develop is the correct counseling approach [6][14].

Special Populations

Men over 65. Vardenafil clearance is reduced by 20% in men over 65, leading the FDA label to recommend a starting dose of 5 mg [4]. Finasteride pharmacokinetics are modestly altered (longer half-life of ~8 hours) but no dose adjustment is needed [5]. The combination remains appropriate with the lower vardenafil starting dose.

Hepatic impairment. Vardenafil AUC increases by 130% in moderate hepatic impairment (Child-Pugh B), requiring a maximum dose of 10 mg [4]. Finasteride is extensively hepatically metabolized, and its label advises caution in liver disease though no specific dose reduction is provided [5]. Clinicians should monitor liver function tests in this population.

Renal impairment. Neither drug requires dose adjustment for renal impairment alone, though vardenafil has not been studied in patients on dialysis [4].

When to Reconsider the Combination

Three scenarios should prompt re-evaluation:

1. The patient's ED worsens or fails to respond to vardenafil 20 mg despite adequate sexual stimulation and timing. Consider finasteride as the cause and trial its discontinuation.
2. The patient develops symptoms consistent with orthostatic hypotension. While finasteride is not the cause, the addition of an alpha-blocker for BPH alongside vardenafil introduces real hypotensive risk.
3. The patient reports mood changes, decreased libido, or ejaculatory dysfunction that predated the start of vardenafil. These are more likely attributable to finasteride's DHT suppression than to PDE5 inhibition.

Patients taking finasteride 5 mg for BPH who develop ED should have a serum testosterone level checked. Finasteride does not lower total testosterone (it may modestly increase it by blocking conversion to DHT), but concurrent hypogonadism is common in the BPH age group and represents an independent, treatable cause of ED [11].